Browser's notes July 2012

July 2012
Skeletal Radiology;Jul2012, Vol. 41 Issue 7, p869
Academic Journal
The article presents abstracts on medical topics which include the treatment of proximal metatarsal V fractures, the effect of long-term alendronate treatment on cortical thickness of the proximal femur and the symptoms of high-grade soft tissue sarcomas.


Related Articles

  • Alendronate-induced unmasking or deterioration of coeliac disease: a case series. Stuckey, B.; Sallie, R. // Osteoporosis International;Jan2015, Vol. 26 Issue 1, p411 

    The article presents several case studies. It states the 60-year-old woman with fracture of the humerus and was diagnosed with bone mineral density (BMD) at the lumbar spine. It highlights the 48-year-old patient with a history of minimal trauma rib fracture with BMD at the lumbar spine and...

  • Alendronic acid tops alfacalcidol for steroid-induced osteoporosis.  // Reactions Weekly;8/26/2006, Issue 1116, p3 

    The article reports on a study which found that treatment with alendronic acid is more effective than alfacalcidol for glucocorticoid-induced osteoporosis in patients with rheumatic diseases.

  • Alendronic acid.  // Reactions Weekly;1/5/2013, Issue 1433, p6 

    The article describes the case of a 69-year-old woman with postmenopausal osteoporosis who developed an atypical femoral subtrochanteric fracture while undergoing alendronic acid therapy.

  • Alendronic acid.  // Reactions Weekly;1/5/2013, Issue 1433, p6 

    The article describes the case of a 75-year-old woman with osteogenesis perfecta who developed an atypical femoral fracture while undergoing alendronic acid.

  • Alendronic acid.  // Reactions Weekly;6/14/2012, Issue 1410, p6 

    The article describes the case of a 76-year-old woman who experienced ulnar and tibial fractures while undergoing long-term treatment with alendronic acid.

  • Alendronic acid/immunosuppressants/nicorandil.  // Reactions Weekly;6/14/2012, Issue 1410, p7 

    The article describes several cases of patients with osteoporosis who experienced osteonecrosis of the jaw while undergoing treatment with alendronic acid, immunosuppressants and/or nicorandil.

  • Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta. Bargman, R.; Posham, R.; Boskey, A.; DiCarlo, E.; Raggio, C.; Pleshko, N. // Osteoporosis International;Mar2012, Vol. 23 Issue 3, p1141 

    Summary: We report a direct comparison of receptor activator of nuclear factor kappa B ligand (RANKL) inhibition (RANK-Fc) with bisphosphonate treatment (alendronate, ALN) from infancy through early adulthood in a mouse model of osteogenesis imperfecta. Both ALN and RANK-Fc decreased fracture...

  • OSTEONECROSIS RELATED TO ORAL BISPHOSPHONATE USAGE: CASE REPORT AND REVIEW OF TREATMENT STRATEGIES. Kilic, Erdem; Gonen, Zeynep Burcin; Alkan, Alper // Journal of International Dental & Medical Research;2012, Vol. 5 Issue 1, p45 

    Bisphosphonates are a class of agents used to treat osteoclast-mediated bone diseases and many neoplasm types. Osteonecrosis of the jaw is a common side effect of bisphosphonate therapy, presenting as exposed and necrotic maxillary and/or mandibular bone. In this report, we present a case of...

  • Erratum to: Vitamin D Status and Bone Mineral Density Changes During Alendronate Treatment in Postmenopausal Osteoporosis. Roux, Christian; Binkley, Neil; Boonen, Steven; Kiel, Douglas; Ralston, Stuart; Reginster, Jean-Yves; Pong, Annpey; Rosenberg, Elizabeth; Santora, Arthur // Calcified Tissue International;Feb2014, Vol. 94 Issue 2, p158 

    No abstract available.


Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics